Technology

CURA Therapeutics is developing the next generation of best/first-in-class multimodal immunotherapies to treat metastatic cancers, pathogen infections, fibrotic diseases, and senescence (longevity). 

CURA's multimodal immunotherapies simultaneously engage immunostimulatory, anti-fibrotic, and anti-senescence activities to treat age-associated diseases, improve healthspan, and increase longevity.

Technological Innovation: Cura's lead immunotherapy CT101 is a multimodal recombinant protein that activates and synchronizes major immune system mechanisms to destroy cancer cells.

1. Induces robust immune effector cell activation and migration in the tumor site.
2. Reduces the immunosuppressive tumor microenvironment.
3. Disrupts the tumor's blood supply, which prevents tumor growth and spread.

Competitive Advantage: Cura Therapeutics competitive advantage is our immunotherapies multimodal approach. Our lead immunotherapy, CT101, is the first-in-class biological drug that contemporaneously engages immunostimulatory, anti-metastatic, and anti-angiogenesis activities against solid malignancies. Currently, no treatments on the market combine these major anti-cancer properties in one drug.

Our lead immunotherapy, CT101, constitutes a new approach to treating patients with metastatic cancer. CT101 has the potential to substantially increase the survival rate and quality of life in patients with metastatic cancer over the current standard of care.

Partnering &
Collaborations

Cura Therapeutics is actively seeking strategic partnering opportunities, and collaborations with pharmaceutical and biotechnology companies to develop and commercialize cancer immunotherapies based on our multifunctional fusion proteins.